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The purpose of this review was to present highlights from the published literature on the topic of the
biology of osteoarthritis (OA). A PubMed search was conducted in order to locate original research
manuscripts published since the last OARSI meeting in 2012. From review of the published literature,
common themes emerged as active areas of research over the past year including studies in the areas of
epigenetics, Wnt signaling, the role of inﬂammatory pathways in OA, lubricin, ﬁbroblast growth factor
signaling, and studies on OA biology in bone. Key ﬁndings in these areas were summarized and impli-
cations for future therapies were discussed.
 2013 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Research into the basic biology of osteoarthritis (OA) continues to
grow with many investigators focused on elucidating mechanisms
relevant to cartilage matrix destruction. However, an accumulating
number of studies have reported ﬁndings in other joint tissues
affected byOA including bone, synovium, ligaments, and themenisci.
Since OA is a disease of the joint as an organ, knowledge of how these
tissues interact to result inOAwill be important andcould lead tonew
approaches for the treatment. This review attempts to capture and
summarize key ﬁndings in the biology of OA published since the last
OARSI meeting in April 2012 up to the end of March 2013.
A PubMed search of English language articles from April 1, 2012
to March 24, 2013 under the search term of osteoarthritis with
MESH terms of embryology, enzymology, etiology, immunology,
metabolism, pathology, physiology, and physiopathology returned
843 published articles. The titles and selected abstracts from this
list were reviewed and publications relevant to the biology of OA
were collected. In addition, selected journals in the ﬁeld were
cross-checked for additional articles of interest that were not
picked up in the PubMed search. Articles more relevant to cartilage
tissue engineering were not included in the review in order to focus
on the biology of OA.R.F. Loeser, Molecular Medi-
er Blvd., Winston-Salem, NC
4.
r@wfubmc.edu.
s Research Society International. PMany of the topic areas covered by Peter van der Kraan in the
2012 review1, such as epigenetics (in particular micro-RNA), Wnt
signaling, autophagy, inﬂammation, obesity/metabolic syndrome,
aging, and the concept of OA as a disease of the joint as an organ,
continued to be active areas of investigation over the past year.
From these topic areas, epigenetics and Wnt signaling were
particularly active areas and so these will be discussed. In addition,
the role of inﬂammatory pathways in OA, including those involved
in innate immune responses, was chosen to highlight along with
selected publications on lubricin, ﬁbroblast growth factor (FGF)
signaling, and studies on OA biology in bone (Table I). It is not
possible to cover all of the excellent work being done in the ﬁeld
and so apologies to those whose work was not included.Epigenetics
Epigenetic regulation of gene transcription allows cells to alter
and ﬁne tune gene expression in response to external cues. Unlike
genetic modiﬁcations which require very long periods of evolu-
tionary pressure to occur, organisms can use epigenetic modiﬁca-
tions to more rapidly respond to changes in the environment.
Individual cells and tissues can likewise use epigenetic modiﬁca-
tions to alter gene expression to respond to changes in their
microenvironment. Many epigenetic modiﬁcations can be main-
tained in cultured cells. It has been observed for quite some time
that chondrocytes removed from an osteoarthritic joint and placed
in culture will maintain an OA-like phenotype for a week or more,
expressing genes seen in OA despite the fact that the cells are noublished by Elsevier Ltd. All rights reserved.
Table I
Major topics and ﬁndings in the biology of OA: 2013
Topic New ﬁndings Therapeutic implications References
Epigenetics Y Methylation of MMP-13, IL-1b, and iNOS promoters.
[ Methylation of Sox-9 promoter.
Altered histone acetylation and differential miRNA
expression in OA chondrocytes.
HDAC inhibitors decrease OA in a mouse
model of OA. DNA methylation and miRNA
expression will be much more difﬁcult to target for therapy.
2e13
Wnt signaling Sclerostin present in articular cartilage.
[ Dkk-1 in OA cartilage and synovium.
[WISP-3/CCN6 in OA cartilage.
Sclerostin inhibition/deletion did not affect the development
of OA in rat or mouse models. Inconclusive results with
Dkk-1 inhibition/overexpression or manipulation of
Wnt/b-catenin activity.
14e20
Inﬂammatory
factors
Production of multiple pro-inﬂammatory mediators
by the injured meniscus.
S100A8 and S100A9 present in OA synovium.
Plasma proteins and soluble CD14 present in SF
which activate TLRs.
CCL2/CCR2 involved in pain in OA.
Y OA in S100A8/A9 / mice in collagenase-induced OA but
not in DMM model.
Y Pain but not OA in CCR2 / mice in the DMM model.
21e28
Lubricin (PRG4) Important boundary lubricant that protects articular
surface.
Overexpression of lubricin reduces OA severity in mouse
models of OA.
29e32
FGF signaling Balance of FGFR1 to FGFR3 mediated signaling
determines catabolic vs anabolic activity of FGFs.
Less severe OA in FGFR1/ mice.
Activation of FGFR3 by FGF-18 more likely to reduce OA than
FGFR1 activation by FGF-2.
33e40
Bone Correlation between cartilage and bone changes in
OA varies by
model system studied, particularly when osteophytes
are examined.
Subsets of OA where bone is a driving factor appear most
likely. Inhibition of cathepsin K Y OA severity in rabbit and
mouse models.
14,41e48
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phenomenon could be explained by epigenetic changes in the cell,
including DNA methylation, histone methylation and acetylation,
and micro (mi)RNAs, which regulate expression of the genes
related to the OA-phenotype.
MMP-13 is a critical enzyme that mediates cartilage matrix
destruction in OA and which appears to be under epigenetic
regulation. Increased MMP-13 expression by human OA chon-
drocytes was associated with demethylation of CpG sites in the
MMP-13 promoter2. A site at 104 bp was studied further and
found to be a site for binding of the cAMP response element-
binding (CREB) when the site was demethylated. In another
MMP-13 promoter study, demethylation at110 bp and299 bp in
human chondrocytes was associated with increased levels of MMP-
13 gene expression3. The same study found similar sites in the IL-1b
promoter. Interestingly, binding of HIF-2a, which was recently
implicated in promoting OA in mice, to the MMP-13 but not IL-1b
promoter, was greater when the two sites were demethylated.
CREBwas not tested but RUNX2, AP-1, and ELF3 regulation of MMP-
13 expression was not altered by methylation status.
Another gene associated with catabolic activity in cartilage is
the inducible nitric oxide synthase (iNOS). A site in the NF-kB
enhancer region was found to be demethylated in human OA
chondrocytes relative to controls and methylation of this region
was associated with decreased iNOS expression4. On the anabolic
side, methylation of the SOX-9 promoter was found to be increased
rather than decreased in human OA cartilage relative to normal
controls5. The demethylating agent 5-azacytidine was able to in-
crease SOX-9 expression demonstrating that methylation was
inhibitory and this appeared to be mediated by altered binding of
the CCAAT-binding factor/nuclear factor-Y and a CREB factor. His-
tone methylation and acetylation may also regulate SOX-9 pro-
moter activity and an increase in H3K9 and H3K27 trimethylation
and a decrease in acetylation at H3K9, 15, 18, 23, and 27 at the SOX-
9 promoter was found.
Histone modiﬁcations can also regulate catabolic mediators in
cartilage. Human chondrocytes induced to express RUNX-2, MMP-3
and ADAMTS-5 by mechanical stress were treated with histone
deacetylase (HDAC) inhibitors MS-275 or trichostatin A (TSA)6. The
HDAC inhibitors reduced expression of all three genes. Likewise, IL-
1-induced expression of MMP-1, MMP-3, andMMP-13 was reducedby treatment of human articular chondrocytes with TSA, MS-275,
or valproic acid7. In further support for an in vivo role for histone
acetylation in OA, TSA treatment of mice reduced the severity of
cartilage damage in the destabilized medial meniscus (DMM)
model of OA7. Thus, studies to date strongly implicate a number of
catabolic and anabolic factors in OA chondrocytes which are
regulated by both methylation and histone modiﬁcations.
In addition to studies in cartilage, differences in DNA methyl-
ation in OA vs osteoporotic bone, taken from the central part of the
femoral head, have been examined8. Out of 241 sites in 228 genes
that were differentially methylated, the vast majority (217) were
found to have reduced methylation in osteoporotic bone. When
these genes were annotated for function, the homeobox super-
family of transcription factors was found to be signiﬁcantly
different between OA and osteoporotic bone. This is of interest
given the important role of this family of transcription factors in
bone and joint development.
Avery active area of epigenetics research in the past year has been
the study of miRNAs although which ones might be important in the
biologyof OA isnot completely clear. Amicroarrayanalysis ofmiRNAs
present in cultured humannormal andOA chondrocytes found seven
miRNAs differentially expressed9. Only one, miR483-5p was
increased in OA cells while the others (miR-149, miR-582-3p, miR-
1227, miR-634, miR576-5p, and miR-641) were at higher levels in
normal chondrocytes. Functional studies were not performed and so
itwas not clearwhat role if any these have inOA. Another study using
human cartilage noted an age-related increase in miR-199a-3p and
miR193b10. In contrast, IL-1b treated human chondrocytes had
decreased levels of miR-199a and this was associated with increased
expression of cyclooxygenase-2 and subsequent PGE-2 production11.
IL-1b treatment of the immortalized C28/I2 chondrocyte line
increasedexpressionofmiRNA-140whichwas found to inhibitMMP-
13 expression12. A previous study had shown that deletion ofmiRNA-
140 inmice resulted in a prematureOAphenotype in associationwith
increased Adamts5 expression13.
Wnt signaling and OA
Wnt signaling plays a key role in the development of the joint
and recent work supports a role in OA as well. Because Wnt path-
ways are involved in both cartilage and bone formation that include
R.F. Loeser / Osteoarthritis and Cartilage 21 (2013) 1436e14421438a role in regulation of chondrocyte hypertrophy in the growth plate,
dysregulation of Wnt pathways in adult tissues could contribute to
the chondrocyte hypertrophy seen in OA and pathologic changes in
cartilage and bone. Sclerostin serves as an inhibitor of Wnt
signaling in bone and loss of function mutations in sclerostin or
inhibition through the use of neutralizing antibodies result in
increased bonemass. In addition to bone, Roudier et al.14 conﬁrmed
earlier reports demonstrating sclerostin was also expressed in
articular cartilage, albeit at similar levels in normal and OA human
cartilage. However, neither genetic deletion of sclerostin in mice or
antibody inhibition in rats altered the development of naturally
occurring OA in mice or surgically-induced OA in rats. Interestingly,
sclerostin knock-out mice at 12 and 16 months of age did not have
more severe cartilage lesions compared to age-matched controls
despite signiﬁcantly increased subchondral bone mass. This ﬁnding
either argues against a direct effect of increased subchondral bone
mass on the overlying cartilage or suggests loss of sclerostin in
cartilage might have counter-acted the effect of increased bone.
Dkks 1-4 are also Wnt antagonists and Dkk-1 and -2 were
reported to be present in articular cartilage with Dkk-1 also found
in human OA synovium15,16. Dkk-1 was increased while Dkk-2 was
decreased in OA cartilage when compared to normal15. In another
study, Dkk-1 and two other Wnt antagonists, Gremlin 1 and
Frizzled-related protein, were found to be expressed at higher
levels in articular cartilagewhen compared to growth plate17. These
Wnt antagonists were shown to inhibit chondrocyte hypertrophy
in vitro suggesting the higher levels in articular cartilage might
serve to inhibit hypertrophy. Dkk-1 overexpression in the mouse
joint by adenoviral injection or by transgenic overexpression
resulted in reduced OA severity in the DMMmodel15. However, the
opposite effect of Dkk-1 on OAwas seen in the rat anterior cruciate
ligament transection (ACLT) model where intra-peritoneal injec-
tion of Dkk-1 antisense oligonucleotides sufﬁcient to reduce the
number of Dkk-1 positive cells in the synovium reduced the
severity of OA rather than increasing it16. Dkk-1 was shown to
inhibit MMP-13 and ADAMTS-4 expression in chondrocytes in
response to theWnt pathway activatorWnt-3a15 while it promoted
production of pro-angiogenic factors and proteinases (ADAMTS-5
and MMP-3) produced by synovial ﬁbroblasts16. If these ﬁndings of
opposite effects in cartilage and synovium are conﬁrmed, it would
suggest that Dkk-1 would not serve as a very good target for
treatment of OA when both tissues are affected.
Adding to the complexity of the role of Wnt signaling in OA, a
study of the Wnt-1-inducible signaling protein 3/CCN6 found that
it was highly expressed in human OA cartilage compared to normal
cartilage and in vitro experiments found that it down-regulated
ADAMTS-5 expression while up-regulating MMP-1018. Activation
of Wnt/b-catenin signaling in primary human chondrocytes
inhibited basal and IL-1b stimulated MMP-1, -3, and -13, possibly
through inhibition of NFkB19. However, another in vitro study found
that Hedgehog proteins stimulated accumulation of superﬁcial
zone protein (lubricin) while antagonists of Wnt/b-catenin also
stimulated lubricin accumulation in explants. Indian hedgehog,
which can regulateWnt signaling as well as PTHrp, was found to be
increased in human OA cartilage and synovium and promote
chondrocyte hypertrophy including increasing MMP-1320. These
studies suggest that a much more complete understanding of Wnt
signaling pathways in cartilage and related joint tissues will be
needed before rational therapeutic interventions can be designed.
Role of inﬂammatory factors in OA
Studies of pro-inﬂammatory mediators found in the OA joint
support the paradigm that although OA may be largely a biome-
chanical disease, its manifestations at the tissue level are mediatedby the activity of inﬂammatory factors. In addition, post-traumatic
OA is an example of a form of OA where both acute inﬂammation
induced by joint injury and abnormal biomechanics resulting from
joint instability likely work in concert to promote joint tissue
destruction. Meniscal injury, either alone or in combination with
an ACL tear, is an important risk factor for knee OA. A study of
meniscal tissue removed during partial meniscectomy in patients
with a meniscal tear, with or without a concomitant ACL tear,
provided evidence that the injured meniscus can be a source of
inﬂammatory mediators in the joint21. Numerous cytokines, che-
mokines, and matrix degrading proteinases were found to be
expressed in the meniscus samples including IL-1a and -b, IL-6,
TNF-a, CCL3, CXCL1, CXCL3, ADAMTS-4 and -5, MMP-1, MMP-9,
and MMP-13.
In a post-traumatic OA model in mice that involves fracture of
the lateral tibial plateau, the role of inﬂammation was studied by
measuring inﬂammatory mediators in the synovial ﬂuid and
expression in the synovium in two different strains of mice22. Male
MRL/MpJ mice developed less severe OA than C57BL/6 mice despite
having a similar joint injury. The C57BL/6 mice were found to have
higher levels of IL-1-a and ILeb in the synovial ﬂuid and greater
expression of TNF-a and IL-1-b as well as the chemokine CCL22 in
synovial tissuewhere a greater inﬁltration of macrophageswas also
found. These ﬁnds support the hypothesis that a more active in-
ﬂammatory response contributed to more severe OA in these mice.
In addition to cytokines and chemokines, many other pro-
inﬂammatory factors have been studied for their potential
involvement in OA including the S100 proteins. S100A8 and
S100A9 are referred to as alarmins or as damage-associated mo-
lecular patterns (DAMPs) since they are released in response to
tissue injury and their presence alarms the innate immune system
that tissue damage has occurred. Both proteins were found to be
present in human synovial tissue removed by biopsy of patients
with early symptomatic OA23. Macrophages are one potential
source of S100 proteins in the joint and in vitro treatment of
macrophages with basic calcium phosphate crystals, which can be
involved in OA, stimulated production of S100A824. Two mouse
models of OA with different levels of synovial inﬂammation were
compared using S100A9 knockout mice (S100A8 knockouts are
not viable and so were not tested). In the less inﬂammatory DMM
model, S100A9 knockout did not protect the articular cartilage
while in the collagenase-induced OA model, where much more
synovitis was noted, knockout mice had less severe synovitis and
cartilage destruction23. In further studies, S100A8 and A9 were
identiﬁed in human OA cartilage and stimulation of chondrocytes
in vitro resulted in increased production of IL-6, IL-8, andMCP-125.
S100A8 and A9 can induce production of pro-inﬂammatory
mediators through Toll-like receptors (TLRs) which are gaining
attention for their role in OA. Inhibition of TLR-4 inhibited catabolic
effects of S100A8 and A9 when chondrocytes were stimulated25.
Additional pro-inﬂammatory mediators, some of which also acti-
vate TLRs, were identiﬁed in human OA synovial ﬂuid using a
proteomics approach26. These included plasma proteins such as Gc-
globulin, a1-microglobulin, and a2-microglobulin. Of interest, this
study also measured the amounts of several cytokines in OA sy-
novial ﬂuids and compared the levels to those in serum. Twowidely
studied cytokines, IL-1b and TNF-a, were present at very low levels
in synovial ﬂuid while IL-6, VEGF, MCP-1, IP-10, and MIG were all
present at higher levels with IP-10 and MIG levels over 1,000-fold
higher than IL-1b26. Another study looked for TLR activators in
synovial ﬂuid from patients with early cartilage damage who were
undergoing arthroscopy to treat a meniscal injury27. This strategy
resulted in the discovery of a TLR co-receptor, soluble CD14, which
augmented the ability of TLR-2 and -4 ligands to stimulate IL-8
release from synovial ﬁbroblasts.
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mediators may also contribute to pain in people with OA. Using the
mouse DMMmodel of OA, Miller et al. showed that themice exhibit
allodynia and discovered that the chemokine MCP-1 (CCL2) and its
receptor CCR2 were increased in the dorsal root ganglia28. CCR2
knockouts exhibited similar cartilage damage to wild type mice
after DMM surgery but had reduced movement-evoked pain
behavior and some resolution of allodynia. A possible role for
macrophages in this process was indicated by the ﬁnding of mac-
rophages in the dorsal root ganglia of the DMM mice which were
reduced in the CCR2 knockouts. These studies support an important
role for macrophages and inﬂammation in OA but suggest that
different factors may contribute to macrophage inﬁltration that
contributes to pain and inﬁltration in the synovium that contrib-
utes to joint tissue destruction.
Protective role of lubricin (PGR4) in OA
Changes in lubrication at the surface of articular cartilage in
response to injury and altered mechanics have emerged as
important in the biology of OA. Much of the recent attention in this
area has been on lubricin which is also known as superﬁcial zone
protein or as proteoglycan protein 4 (PRG4). When compared to
normal synovial ﬂuid, synovial ﬂuid from human OA joints that had
reduced lubricin levels was found to have reduced cartilage
boundary-lubricating ability when tested in a friction test29. Sup-
plementing these samples with lubricin restored the lubricating
ability. Testing done in lubricin knockout mice demonstrated in-
creases in joint friction and chondrocyte apoptosis in the superﬁcial
cartilage that appeared to be related30. Loss of lubricin from the
articular surface was seen in the rat ACLT model. Supplementation
with lubricin by intra-articular injection improved weight bearing
in a measurement of hind limb force and reduced the level of uri-
nary CTX-II but did not alter the OARSI score31.
Finally, in a very exciting study32 over-expression of lubricin in
transgenic mice reduced the severity of both age-related OA (tested
at 10 months of age) as well as in a cruciate ligament transection
model of OA. The severity of post-traumatic OAwas also reduced by
expressing lubricin in the mouse knee joint using intra-articular
injection of adeno-associated virus, even when injected 2 weeks
after the joint injury. The study went on to examine how lubricin
affected gene transcription using superﬁcial chondrocytes for RNA
isolation and analysis by microarrays. It was discovered that
expression of lubricin inhibited expression of genes involved in
cartilage catabolism and chondrocyte hypertrophy in association
with an up-regulation of HIF-3a, a negative regulator of HIF-1a and
HIF-2a. The authors proposed that the increase in HIF-3a may
correct the imbalance in catabolic and anabolic activity that pro-
motes OA through down-regulation of HIF-1a and HIF-2a32. These
studies support further investigation of lubricin (PRG4, SZP) as a
therapeutic agent for human OA, perhaps given as soon as possible
after an acute joint injury to prevent post-traumatic OA.
The role of altered FGF signaling in OA
Unlike the consistent pro-anabolic effects observedwith FGF-18,
FGF-2 effects in adult articular cartilage have been less clear. Previ-
ous in vitro experiments found FGF-2 stimulated chondrocyte pro-
liferation, inhibited matrix synthesis, and promoted MMP-13
production33,34. FGF-2 released when cartilage is cut with a scalpel
ex vivo (aproposedmodelof cartilage injury) resulted inactivationof
MAP kinases and IKK35 that might be expected to promote pro-
inﬂammatory gene expression. However, FGF-2 knockout mice
were found to develop accelerated OA with aging and more severe
OA in the DMM model36. Experiments showing differences in theresponse of human and mouse cartilage to FGF-2 suggested that
differences in expression of FGF receptors (FGFR)-1 and FGFR-3
might be to blame for the inconsistent ﬁndings37. Earlier studies
had shown deletion of FGFR-3 in mice resulted in spontaneous OA
suggesting FGF-2 activationof FGFR-3might be chondroprotective38
while FGFR-1 was proposed to mediate catabolic effects of FGF-2
based on in vitro experiments. In support of catabolic activity in
response to FGFR-1 activation, Weng et al. found that FGFR-1 deﬁ-
cient mice developed less severe age-related aggrecan loss at 12
months and less severe OA in younger mice using the DMM model
that was associated with decreased expression of MMP-13 and
interestingly higher expression of FGFR-339.
Taken together, these studies suggest that the ratio of FGFR-1
and FGFR-3 in articular cartilage determines the response of
chondrocytes to FGF stimulation such that an excess of FGFR-1
stimulation relative to FGFR-3 would promote cartilage catabo-
lism and the development of OA. Previous work had demonstrated
the ratio of FGFR-3 to FGFR-1 was reduced in OA40. This is similar to
the ﬁnding that the ratio of the TGF-b receptors Alk-1 and Alk-5
determine the response to TGF-b stimulation such that an
increased Alk-1 to Alk-5 ratio in OA is pro-catabolic. Since FGF-2 can
stimulate either FGFR-1 or FGFR-3 and TGF-b can stimulate either
Alk-1 or Alk-5, they would be unlikely to be of much beneﬁt in
treating OA when the relative receptor levels favor catabolic over
anabolic activity. However, FGF-18 primarily stimulates FGFR-3 and
so would be expected to promote anabolic over catabolic activity
making it a better choice for treating OA. Currently, intra-articular
FGF-18 is in early phase studies as an anabolic agent to promote
cartilage repair and to treat OA (clinicaltrials.gov).
Bone
The role of bone in the biology of OA has been an active area of
investigation. Although OA changes in the articular cartilage in
some humans and animal models (see above studies on the DMM
model in mice) can be seen in the absence of signiﬁcant synovitis,
involvement of bone proximate to the affected joint seems to be
universal during at least some stage of OA. However, various studies
reported during the last year that used either human tissue or
animal models found both a good correlation between changes
occurring in bone and in the overlying articular cartilage or a poor
correlation between the two. Human osteochondral plugs taken
from tibial plateaus with a range of cartilage damagewere found by
micro-CT to have changes in subchondral bone mineralization and
bone volume underneath the samples with the most severe carti-
lage changes41. The same group published a second study investi-
gating the contribution of excessive loading and endochondral
ossiﬁcation to the subchondral bone changes seen in OA and
concluded that both processes were responsible42.
Studies in various mouse models of OA noted both a good and
poor correlation between cartilage and bone changes. A study using
the DMM model to compare OA severity in a strain of mice
(LGXSM-6) noted to be “super healers” and a strain (LGXSM-33)
noted to be “poor healers” of cartilage and ear punch lesions found
that the more severe cartilage lesions in the poor healer strain
correlated with more severe bone changes measured by micro-
CT43. Likewise, bone targeted overexpression of EphB4 resulted in
reduced cartilage damage in the DMMmodel that correlated with a
reduction in subchondral sclerosis and bone volume as well as the
number of tartrate-resistant acid phosphatase-positive osteo-
clasts44. In contrast to these studies, compared to wild-type con-
trols, Col6a1/mice surprisingly had less knee joint cartilage loss
at 15 months of age despite large osteophytes which appeared as
early as 2 months of age45. As noted above, sclerostin knockouts did
not exhibit age-related OA at 12 or 16 months of age despite a
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study of the DMM model in 12 week old C57BL/6 mice found sig-
niﬁcant osteophyte (chondrophyte) formation at 2 weeks after
DMM surgery which was a time point when the articular cartilage
damage was minimal46. In that study, the size of the medial abaxial
osteophytes did not progress from 2 to 16 weeks while the cartilage
damage and subchondral bone thickening did progress.
Differences in osteophyte formation and cartilage damage were
also noted in studies examining the effect of cathepsin K inhibition
on the development of OA. Cathepsin K, a protease produced by
osteoclasts and involved in bone resorption, has also been shown to
be made by synovial ﬁbroblasts and chondrocytes. A recent study
found it can contribute to type II collagen cleavage seen with aging
and in OA47. Treatment of rabbits with a chemical inhibitor of
cathepsin K (L-235) reduced cartilage damagemeasured byMankin
scoring in the ACLT model and cathepsin K knockout mice likewise
had reduced cartilage damage after ACLT surgery48. In both models,
inhibition of cathepsin K protected the subchondral bone. However,
a signiﬁcant reduction in osteophytes was only seen in the rabbit
ACLT model where the chemical inhibitor was only partially pro-
tective in terms of cartilage damage while in the cathepsin K /
mice no reduction in osteophytes was seen despite a very signiﬁ-
cant reduction in the Mankin score.Conclusions
The various tissues involved in the OA process and a host of
potential mediators that contribute to the development of OA
continue to be deﬁned (Fig. 1). The ultimate goal of research on the
biology of OA is to discover new therapeutic targets based on a
better understanding of disease mechanisms. Although epigenetic
regulation of gene transcription and Wnt signaling both appear to
contribute to the OA process, the complexity of the interacting
systems involved and the difﬁculty in targeting one aspect of their
activity, which might be beneﬁcial in OA, without affecting another
aspect that would be harmful, will make these areas difﬁcult to
translate to new therapeutics. It is not to say that they are not
important areas for continued research but rather translation to the
clinic will require more precisely deﬁned targets and will be much
slower than in other areas.
The knowledge of the role of inﬂammation in OA is rapidly
expanding and there is evidence that pro-inﬂammatory mediators
can be produced by all of the joint tissues affected by OA. The limi-
tation in this area of research is that no single target stands out above
the others. Unlike in RA, where targeting TNFa results in signiﬁcant
improvement in symptoms and disease progression inmany (but not
all) patients, it appears that in OA there may be subsets of patients
where inﬂammation is a driving force and within this subset more
than one pro-inﬂammatory mediator may need to be inhibited. It isFig. 1. Interactions among tissues and biological mediators that contribute to the
biology of OA.very possible, as noted by thework on the chemokine receptor CCR2,
that pro-inﬂammatory mediators responsible for pain differ from
those responsible for joint tissue destruction.
Closer to translation as new therapeutics for knee OA, intra-
articular treatment with lubricin or with anabolic factors, such as
FGF-18, is supported by recent work on the biology of OA. The
ﬁnding that an injection of lubricin given 2 weeks after a joint
injury can reduce the severity of subsequent OA in mice suggests
that it could be a useful treatment to prevent post-traumatic OA.
The ability of FGF-18 to activate FGFR3 and promote anabolic ac-
tivity in joint tissues holds promise with the caveat that a loss of
FGFR3 and gain of FGFR1 in OA cartilage could limit its effectiveness
at more advanced stages of disease.
Finally, a review of the most recent literature on bone in OA
supports the long-held belief that bone is involved in the OA dis-
ease process. However, the association between changes in bone
and destruction of the overlying cartilage is not consistent, partic-
ularly in regards to osteophyte formation. This suggests that,
similar to the role of inﬂammation, there are likely to be subsets of
OA where bone is a driving factor in the disease process and
osteophytes are not the best marker to deﬁne these subsets.
Missing from this review is a discussion of the focal areas of bone
remodeling that can be detected by imagingmodalities such as MRI
and which may be important in pain and/or disease progression.
Clearly the OA ﬁeld is rapidly advancing but a better understanding
of the biology of the disease that can translate to new therapeutics
will require a division of OA into subsets of disease which will have
different etiologies rather than lumping all of OA into a single
disease process.
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